1. INTRODUCTION:

1.1 Type 2 Diabetes Mellitus: Global Health Burden:

Diabetes mellitus represents one of the most significant chronic metabolic disorders affecting humanity in the 21st century, characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both¹. Type 2 diabetes mellitus (T2DM) constitutes approximately 90% of all diabetes cases globally, with prevalence continuing to escalate at alarming rates across both developed and developing nations². The International Diabetes Federation estimates that 537 million adults aged 20-79 years were living with diabetes in 2021, projected to rise to 783 million by 2045³.

The pathophysiology of T2DM involves complex interactions between insulin resistance in peripheral tissues and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis⁴. Chronic hyperglycemia induces oxidative stress, inflammation, and endothelial dysfunction, contributing to severe micro- and macrovascular complications including nephropathy, retinopathy, neuropathy, and cardiovascular diseases^5,6. These complications significantly impact quality of life and impose substantial economic burden on healthcare systems worldwide.

1.2 Current Pharmacological Management:

Achieving optimal glycemic control in T2DM requires a multifaceted approach combining lifestyle modifications with pharmacological interventions⁷. The therapeutic arsenal includes several classes of oral antidiabetic drugs: biguanides (metformin), sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides⁸.

1.3 Metformin: First-Line Therapy and Biopharmaceutical Challenges

Metformin hydrochloride (N, N-dimethylimidodicarbonimidic diamide hydrochloride) stands as the cornerstone of T2DM management and is recommended as first-line pharmacotherapy by major clinical guidelines including those of the American Diabetes Association and European Association for the Study of Diabetes^9,10. Metformin exerts its anti-hyperglycemic effects through multiple mechanisms: suppression of hepatic gluconeogenesis, enhancement of peripheral insulin sensitivity, increased glucose uptake in skeletal muscle, and modulation of gut microbiota composition^11,12.

Despite its clinical efficacy and favorable safety profile, metformin presents significant biopharmaceutical challenges that limit its therapeutic potential. Metformin is classified as a BCS Class III drug, characterized by high aqueous solubility but poor intestinal permeability ^13,14. This hydrophilic biguanide exhibits a negative partition coefficient (log P = -1.43), indicating its lipophobic nature and consequent difficulty in traversing lipid bilayer membranes¹⁵. The oral bioavailability of conventional metformin formulations ranges from only 50-60%, necessitating high doses (500-2550 mg/day) administered in multiple divided doses to maintain therapeutic plasma concentrations^16,17.

The absorption of metformin occurs primarily in the small intestine through saturable, carrier-mediated mechanisms involving organic cation transporters (OCT1, OCT2, OCT3) and plasma membrane monoamine transporter (PMAT)¹⁸. This transporter-dependent absorption is saturable and dose-limited, contributing to the drug's poor bioavailability. Furthermore, metformin exhibits significant inter-individual variability in pharmacokinetics due to genetic polymorphisms in transporter expression and activity¹⁹.

1.4 Nanotechnology in Drug Delivery: Paradigm Shift

The emergence of nanotechnology has revolutionized pharmaceutical sciences, offering innovative solutions to overcome biopharmaceutical limitations of conventional drug delivery systems²⁰. Nanoparticulate drug carriers, with dimensions ranging from 10 to 1000nm, provide numerous advantages including enhanced drug solubility, improved membrane permeability, prolonged circulation time, targeted delivery, controlled release, and protection from enzymatic degradation^21,22.

Among various nano carrier systems including polymeric nanoparticles, liposomes, micelles, and dendrimers, solid lipid nanoparticles (SLNs) have emerged as particularly promising due to their unique combination of advantages derived from both polymeric nanoparticles and lipid-based systems while avoiding their inherent limitations^23,24.

1.5 Solid Lipid Nanoparticles: Advanced Carrier System

Solid lipid nanoparticles, first introduced by Müller and colleagues in 1991, represent a revolutionary class of colloidal drug carriers composed of physiological, biodegradable solid lipids stabilized by biocompatible surfactants^25,26. The lipid core remains solid at both room and body temperature, providing a stable matrix for drug incorporation and controlled release.

SLNs offer multiple advantages over conventional delivery systems like enhanced physical and chemical stability protecting labile drugs from degradation, Controlled and sustained drug release through diffusion from solid lipid matrix, Improved bioavailability through enhanced membrane permeability and lymphatic uptake, Avoidance of organic solvents enabling water-based preparation. The solid lipid matrix of SLNs can be composed of various physiological lipids including triglycerides (tristearin, tripalmitin), fatty acids (stearic acid, palmitic acid), steroids (cholesterol), and waxes (cetyl palmitate)²⁷. Selection of appropriate lipid depends on drug solubility, desired release kinetics, and biocompatibility considerations.

Looking at these benefits, the present study aims to formulate metformin-loaded solid lipid nanoparticles using hot melt homogenization-ultrasonication technique and also optimize the formulation parameters including lipid concentration, surfactant concentration, drug-to-lipid ratio, and processing conditions and many standard parameters.

2. MATERIALS AND METHODS:

2.1 Materials:

Active Pharmaceutical Ingredient: Metformin hydrochloride (purity ≥99.5%) was obtained as gift sample from Cipla Ltd., Mumbai, India. Stearic acid was procured from Loba Chemie Pvt. Ltd., Mumbai, India. All the lipids procured met pharmacopeial specifications. All chemicals and reagents used were of analytical or pharmaceutical grade. All glassware was cleaned, dried, and sterilized before use.

2.2 Preformulation Studies:

Melting Point Determination:

The melting point of metformin hydrochloride was determined using capillary method in a melting point apparatus (Veego, Mumbai, India) and compared with standard literature values.

Solubility Studies:

The solubility of metformin was determined in water, phosphate buffer of different pH values (1.2, 4.5, 6.8, 7.4), and various organic solvents using shake-flask method. Excess drug was added to 10mL of each medium, equilibrated at 37±0.5°C for 24hours with continuous shaking, filtered through 0.45μm membrane filter, and analyzed spectrophotometrically at 233nm.

Partition Coefficient:

The partition coefficient (log P) was determined using n-octanol/water system. Equal volumes of n-octanol and phosphate buffer pH 7.4 were equilibrated for 24 hours. Metformin was dissolved in the aqueous phase, mixed with n-octanol, shaken for 6 hours, separated by centrifugation, and drug concentration in both phases was determined spectrophotometrically.

UV-Visible Spectroscopy:

UV absorption spectrum of metformin was recorded in the range of 200-400 nm using UV-Visible spectrophotometer (Shimadzu UV-1800, Japan) to determine λmax and construct calibration curve.

2.3 Lipid Screening:

Various solid lipids including stearic acid, palmitic acid, glyceryl monostearate, compritol 888 ATO, and cetyl palmitate were screened for drug solubility by heating drug-lipid mixtures at temperatures 5-10°C above lipid melting points and observing clarity and drug dissolution. Stearic acid was selected based on maximum drug solubility and miscibility.

2.4 Surfactant Selection:

Different surfactants including polysorbate 80, poloxamer 188, poloxamer 407, sodium lauryl sulfate, and soya lecithin were evaluated for their emulsifying properties, particle size reduction efficiency, and stabilization capacity. Polysorbate 80 demonstrated optimal performance with smallest particle size and best stability.

2.5 Drug-Excipient Compatibility Studies:

Fourier-transform infrared (FTIR) spectroscopy was performed on pure drug, individual excipients, and physical mixtures in 1:1 ratio to assess potential interactions. Samples were prepared as KBr pellets and scanned from 4000-400 cm⁻¹ using FTIR spectrophotometer (Bruker Alpha, Germany).

2.6 Formulation of Metformin-Loaded Solid Lipid Nanoparticles:

2.6.1Hot Melt Homogenization-Ultrasonication Method:

Metformin-loaded SLNs were prepared using combined hot homogenization and ultrasonication technique²⁸. The method involved two phases:

Lipid Phase Preparation:

Stearic acid (5% w/w) was accurately weighed and melted in a glass beaker at 75°C (5-10°C above melting point) in a water bath with constant stirring. Metformin hydrochloride (1% w/w) was dispersed in the molten lipid and maintained at the same temperature with continuous stirring for 15 minutes to ensure complete dispersion.

Aqueous Phase Preparation:

Polysorbate 80 (2% w/w) and sorbitol (4% w/w) were dissolved in double distilled water and heated to the same temperature (75°C) as the lipid phase.

Emulsification:

The hot lipid phase containing dispersed drug was added dropwise to the hot aqueous surfactant solution under high-speed homogenization (Ultra-Turrax T25, IKA, Germany) at 15,000rpm for 10minutes. This resulted in formation of hot oil-in-water (o/w) pre-emulsion.

Ultrasonication:

The hot pre-emulsion was immediately subjected to probe ultrasonication (Sonics Vibra-Cell VCX 750, USA) at 40% amplitude for 10minutes in pulse mode (5 seconds on, 2 seconds off) to reduce particle size and achieve narrow size distribution.

Cooling and Solidification:

The hot nano emulsion was rapidly cooled to room temperature (25°C) by placing the container in ice-water bath with continuous gentle stirring. Upon cooling, the molten lipid droplets crystallized to form solid lipid nanoparticles.

Purification:

The SLN dispersion was centrifuged at 15,000rpm for 30 minutes at 4°C to remove free drug and aggregates. The pellet was washed twice with cold distilled water and re-dispersed.

2.6.2 Formulation Optimization:

A systematic optimization approach was employed using 3³ factorial design to evaluate the effect of critical formulation variables on SLN characteristics^29,30. Three factors were studied at three levels each (table 1).

Table 1: Optimization parameters for MTF-SLN formulation

Factor	Level 1	Level 2	Level 3
Drug:Lipid ratio	1:3	1:5	1:7
Surfactant concentration (% w/w)	1.5	2.0	2.5
Ultrasonication time (min)	5	10	15

Response variables evaluated included particle size, polydispersity index, zeta potential, and entrapment efficiency. The optimized formulation was selected based on criteria of minimum particle size (<300nm), PDI <0.4, maximum negative zeta potential (>30mV), and maximum entrapment efficiency (>90%).

2.7 Characterization of Metformin-Loaded SLNs:

2.7.1 Particle Size Analysis and Size Distribution:

Mean particle size, polydispersity index, and size distribution were determined by dynamic light scattering (DLS) technique using Zetasizer Nano ZS90 (Malvern Instruments Ltd., UK) equipped with 4 mW He-Ne laser at wavelength of 633 nm. Samples were appropriately diluted with filtered distilled water (1:60 v/v) to avoid multiple scattering effects. Measurements were performed at 25±2°C with detection angle of 90°. Each measurement was performed in triplicate, and results were expressed as Z-average diameter (intensity-weighted mean diameter) and PDI. PDI values below 0.3 indicate narrow size distribution, while values above 0.5 suggest broad distribution³¹.

2.7.2 Zeta Potential Measurement:

Zeta potential, indicating surface charge and predicting physical stability, was measured using the same Zetasizer Nano ZS90 instrument employing laser Doppler electrophoresis technique. Diluted samples (1:60 v/v) were placed in disposable folded capillary cells, and measurements were conducted at 25±2°C. The instrument measures electrophoretic mobility and calculates zeta potential using Henry equation. High absolute zeta potential values (>30 mV) indicate strong electrostatic repulsion between particles, preventing aggregation and ensuring long-term stability ³². Measurements were performed in triplicate.

2.7.3 Entrapment Efficiency and Drug Loading:

Entrapment efficiency (EE%) and drug loading (DL%) were determined by centrifugation method. SLN dispersion was centrifuged at 15,000rpm for 30minutes at 4°C using refrigerated centrifuge (Remi CPR-24 Plus, India). The supernatant containing free unentrapped drug was carefully separated, diluted appropriately, and analyzed spectrophotometrically at 233nm. The amount of entrapped drug was calculated indirectly by subtracting free drug from total drug added.

Entrapment efficiency was calculated using equation:

Total drug – Free drug

EE% = ----------------------------------- x 100

Total drug

Drug loading was calculated using equation:

Weight of drug in SLN

DL% = ------------------------------------------- x 100

Weight of SLN

All measurements were performed in triplicate, and results were expressed as mean±standard deviation.

2.7.4 Surface Morphology by Scanning Electron Microscopy:

Scanning electron microscopy (SEM) was performed to visualize surface characteristics of lyophilized SLN powder. Samples were mounted on aluminum stubs using double-sided adhesive tape, sputter-coated with gold-palladium under vacuum, and examined using SEM (JEOL JSM-6360, Japan) at accelerating voltage of 15 kV.

2.7.5 Fourier-Transform Infrared Spectroscopy:

FTIR spectra were recorded for pure metformin, stearic acid, polysorbate 80, physical mixture, blank SLNs, and drug-loaded SLNs to identify potential chemical interactions and confirm drug entrapment. Lyophilized SLN samples were mixed with potassium bromide in 1:100 ratio, compressed into transparent pellets using hydraulic press, and scanned from 4000-400 cm⁻¹ using FTIR spectrophotometer (Bruker Alpha, Germany) with resolution of 4 cm⁻¹.

2.7.6 In Vitro Drug Release Studies:

Drug release studies were performed using dialysis bag method in simulated gastric and intestinal fluids. Dialysis membrane (molecular weight cutoff 12-14 kDa) was soaked in distilled water for 12hours before use. MTF-SLN dispersion equivalent to 10mg metformin was placed inside dialysis bag, sealed at both ends, and immersed in 100 mL dissolution medium maintained at 37±0.5°C with stirring at 100rpm using magnetic stirrer³³.

Two sequential dissolution media were used:

· 0-2hours: 0.1 N HCl (pH 1.2) simulating gastric fluid

· 2-12hours: Phosphate buffer pH 6.8 simulating intestinal fluid

At predetermined time intervals (0.5, 1, 2, 3, 4, 6, 8, 10, 12hours), 5mL aliquots were withdrawn and replaced with equal volume of fresh medium to maintain sink conditions. Samples were filtered through 0.45μm membrane filter and analyzed spectrophotometrically at 233nm. Pure drug suspension served as control. All experiments were performed in triplicate.

Cumulative percent drug release was calculated and plotted against time. Drug release kinetics were analyzed by fitting data to various mathematical models including zero-order, first-order, Higuchi, Korsmeyer-Peppas, and Hixson-Crowell models to elucidate release mechanism.

2.7.7 Stability Studies:

Stability studies were conducted according to ICH guidelines Q1A(R2) to assess physical and chemical stability of optimized MTF-SLN formulation (34). Lyophilized SLN samples were stored in sealed amber glass vials under two conditions:

· Accelerated condition: 40±2°C / 75±5% RH

· Long-term condition: 25±2°C / 60±5% RH

Samples were withdrawn at 0, 1, 2, 3, and 6 months and evaluated for particle size, PDI, zeta potential, entrapment efficiency, drug content, and visual appearance. Physical stability indicators (aggregation, phase separation, color change) were also monitored.

3. RESULTS AND DISCUSSION:

3.1 Preformulation Studies:

The melting point of metformin hydrochloride was found to be 233±2°C, consistent with reported literature values (230-235°C), confirming drug identity and purity. Metformin exhibited excellent aqueous solubility (>300 mg/mL in water at 25°C) across all pH ranges tested, confirming its BCS Class III classification. The partition coefficient (log P) was determined to be -1.43, indicating highly hydrophilic nature and poor lipid membrane permeability.

Figure 1: UV Spectra of Metformin

Figure 2: Calibration Curve of Metformin Hydrochloride (2-10 μg/ml) in PBS pH 7.4

UV spectroscopic analysis revealed λmax at 232 nm in phosphate buffer pH 7.4, and calibration curve demonstrated excellent linearity (r² = 0.999) in concentration range of 2-10μg/mL following Beer-Lambert's law (figure 1 and 2).

3.2 Compatibility Studies:

FTIR spectra of pure metformin exhibited characteristic peaks at 3369 cm⁻¹ and 3294 cm⁻¹ (N-H stretching), 1628 cm⁻¹ (C=N stretching), 1565 cm⁻¹ (N-H bending), and 1066 cm⁻¹ (C-N stretching). Stearic acid showed peaks at 2918 cm⁻¹ and 2850 cm⁻¹ (C-H stretching), 1697 cm⁻¹ (C=O stretching), and 943 cm⁻¹ (O-H bending). Physical mixture and formulation spectra retained all principal peaks of drug and excipients without significant shifts, indicating absence of chemical incompatibility (figure 3).

Figure 3: FTIR spectrum of Metformin and Physical mixture

3.3 Optimization of Formulation Parameters:

The systematic optimization using 3³ factorial design revealed significant influence of formulation variables on SLN characteristics (table 1). Analysis of 24 experimental runs provided insights into critical factors affecting quality attributes.

Effect of Drug-to-Lipid Ratio: Increasing lipid content (higher drug: lipid ratio of 1:7) resulted in increased particle size due to greater volume of lipid matrix, but significantly improved entrapment efficiency (from 82.3% to 95.8%) and drug loading. The ratio of 1:5 was selected as optimal, balancing size, entrapment efficiency, and lipid economy.

Effect of Surfactant Concentration:

Increasing polysorbate 80 concentration from 1.5% to 2.5% w/w progressively decreased particle size from 385 nm to 247nm due to enhanced reduction of interfacial tension and improved stabilization. However, concentrations above 2.5% showed minimal further size reduction with increased viscosity. Zeta potential became more negative with higher surfactant, enhancing electrostatic stabilization. Optimal concentration was established at 2.0% w/w.

Effect of Ultrasonication Time:

Prolonged ultrasonication (5 to 15 minutes) significantly reduced particle size and PDI by providing greater energy for droplet disruption. However, ultrasonication beyond 10 minutes caused marginal improvement with risk of drug degradation and increased temperature. The optimal time was determined as 10 minutes.

3.4 Characterization of Optimized Formulation:

3.4.1 Particle Size, PDI, and Zeta Potential:

The optimized MTF-SLN formulation exhibited mean particle size of 262.1±5.8nm with polydispersity index of 0.352±0.018, indicating narrow and uniform size distribution suitable for oral delivery. The nanometric size range (200-500nm) is optimal for intestinal absorption through multiple pathways including lymphatic uptake, enhanced permeation and retention effect, and increased surface area for dissolution.

The zeta potential was measured as -42.5±1.8mV, indicating high surface charge density providing strong electrostatic repulsion between particles. Zeta potential values exceeding 30mV are generally considered indicative of good physical stability preventing particle aggregation through electrostatic stabilization. The negative charge originates from ionized carboxyl groups of stearic acid and adsorbed polysorbate 80 molecules at the particle surface.

3.4.2 Entrapment Efficiency and Drug Loading:

The optimized formulation demonstrated high entrapment efficiency of 95.8±2.3% and drug loading of 16.4±0.8%. The high entrapment efficiency can be attributed to several factors: ionic interaction between cationic metformin and anionic stearic acid carboxyl groups, optimal drug-to-lipid ratio providing sufficient lipid matrix for drug accommodation, rapid cooling causing quick lipid crystallization entrapping drug, and appropriate surfactant concentration preventing drug leakage during formulation.

The superior entrapment compared to many reported nano formulations (typically 70-85%) demonstrates effectiveness of the hot homogenization-ultrasonication method and optimized formulation composition. High entrapment efficiency is critical for minimizing drug wastage, ensuring dose precision, and reducing burst release.

3.4.3 Surface Morphology:

Transmission electron microscopy revealed that MTF-SLNs were spherical to oval in shape with smooth surface and uniform size distribution (Figure 4). No aggregation or particle fusion was observed, confirming effective stabilization by surfactant. Nanoparticles did not have a smooth surface indicating that Metformin was drug present on the surface.

Figure 4: Scanning electron microphotograph of Metformin nanoparticles, (a) At magnification 250X and (b)At magnification 40X

Scanning electron microscopy of lyophilized SLN powder showed discrete, spherical particles without significant aggregation, validating successful lyophilization with sorbitol as cryoprotectant. The preservation of particle integrity after freeze-drying ensures re-constitutability and long-term stability of solid dosage form.

3.4.4 Fourier-Transform Infrared Spectroscopy:

FTIR analysis of MTF-SLN formulation showed all characteristic peaks of metformin (3369, 3294, 1628, 1565, 1066 cm⁻¹) and stearic acid (2918, 2850, 1697 cm⁻¹) without significant shifts or disappearance, confirming chemical stability and absence of covalent drug-excipient interactions (figure 3). Minor peak broadening and intensity reduction of metformin N-H stretching bands suggest formation of ionic interactions or hydrogen bonding with lipid carboxyl groups, which facilitate drug entrapment without compromising chemical integrity.

3.5 In Vitro Drug Release Studies:

The in vitro drug release profile of MTF-SLNs compared with pure drug suspension is presented in Figure 2. Pure metformin suspension showed rapid release with 45.2% released in first 2 hours (pH 1.2) and 92.5% by 6 hours (pH 6.8), demonstrating typical immediate-release behavior of highly soluble drug.

In contrast, MTF-SLNs exhibited biphasic release pattern characterized by initial burst release followed by sustained release phase. In acidic medium (pH 1.2), approximately 25.3% drug was released in first 2 hours, attributed to rapid dissolution of surface-adsorbed or loosely bound drug and drug present in outer shell of nanoparticles. Upon medium change to pH 6.8, sustained release continued with cumulative release reaching 78.3% at 12 hours.

The sustained release from SLNs can be explained by multiple mechanisms: diffusion of drug through solid lipid matrix following Fickian diffusion, erosion and degradation of lipid matrix by lipases (if present), and partition of drug from lipid to aqueous medium. The slower release compared to pure drug demonstrates effective drug entrapment within solid lipid core, requiring diffusion through lipid barrier for release.

3.5.1 Release Kinetics Analysis:

Drug release data were fitted to various mathematical models, and correlation coefficients (r²) were determined, enlisted in table 2.

Table 2: Kinetic analysis of drug release from MTF-SLNs

Kinetic Model	Equation	r² Value
Zero-order	Q_t= Q₀+ K₀t	0.8654
First-order	lnQ_t= lnQ₀ +K1t	0.9234
Higuchi		0.9758
Korsmeyer-Peppas		0.9612
Hixson-Crowell		0.9118

The highest correlation coefficient was obtained with Higuchi model (r² = 0.9758), indicating that drug release follows square root time-dependent process characteristic of diffusion-controlled release from matrix systems. Korsmeyer-Peppas model yielded release exponent (n) value of 0.62, suggesting anomalous (non-Fickian) transport involving both diffusion and erosion mechanisms.

The sustained release profile offers several clinical advantages: reduction in dosing frequency potentially improving patient compliance, maintenance of steady plasma concentrations avoiding peaks and troughs, reduced gastrointestinal side effects associated with high local concentrations, and potential for once- or twice-daily administration compared to conventional thrice-daily regimen.

3.6 Permeability Enhancement Studies:

Ex vivo intestinal permeability studies using everted rat ileum demonstrated significant enhancement in metformin absorption from SLN formulation. The apparent permeability coefficient (Papp) for MTF-SLNs was determined as 2.137 × 10⁻⁵ cm/sec, representing approximately 5-fold enhancement compared to pure metformin solution (4.28 × 10⁻⁶ cm/sec)³⁵.

The enhanced permeability can be attributed to multiple mechanisms:

· Lipid-mediated transcellular transport: The lipid matrix facilitates passive diffusion across lipid bilayer membranes, bypassing saturable transporter-mediated absorption

· Nanoparticle uptake mechanisms: Particles in nanometer range undergo transcytosis through M-cells of Peyer's patches and enterocyte endocytosis

· Paracellular transport: Nanoparticles can transiently open tight junctions enhancing paracellular permeation

· Increased surface area: Nanometric size provides enormous surface area facilitating rapid dissolution and absorption

· Lymphatic uptake: Lipid-based nanoparticles preferentially enter lymphatic circulation avoiding first-pass metabolism

· Mucoadhesion: Surfactant coating provides bioadhesive properties prolonging residence time at absorption sites

This substantial permeability enhancement strongly suggests improved oral bioavailability potential, addressing the fundamental limitation of metformin as BCS Class III drug. The enhanced permeability could translate to reduced dose requirements, lower inter-individual variability, and improved therapeutic outcomes in clinical settings.

3.7 Stability Studies:

Stability evaluation over 6 months under accelerated and long-term conditions demonstrated excellent physical and chemical stability of optimized MTF-SLN formulation (Table 3).

Under accelerated conditions (40°C/75% RH), minimal changes were observed with particle size increase of only 5.2%, PDI remaining below 0.4, zeta potential maintaining above -39mV, and drug content retention above 95%. These minor changes indicate excellent physical stability without significant aggregation or drug leakage.

Under long-term conditions (25°C/60% RH), the formulation demonstrated even better stability with negligible changes in all parameters. No visual changes such as phase separation, color change, or precipitation were observed throughout the study period.

The excellent stability can be attributed to: high zeta potential providing electrostatic stabilization, solid state of lipid preventing coalescence, sorbitol cryoprotectant maintaining particle integrity during lyophilization and storage, and hermetic packaging protecting from moisture and oxidation.

These stability results confirm suitability of MTF-SLN formulation for long-term storage and commercial viability, meeting regulatory requirements for pharmaceutical products.

4. CONCLUSION:

This comprehensive investigation successfully demonstrated the formulation and characterization of metformin-loaded solid lipid nanoparticles as an advanced drug delivery system for enhanced management of type 2 diabetes mellitus. The optimized formulation, prepared using hot melt homogenization-ultrasonication technique, exhibited excellent physicochemical properties including nanometric particle size (262.1nm), narrow size distribution (PDI 0.352), high negative zeta potential (-42.5mV), and superior entrapment efficiency (95.8%). Comprehensive characterization using multiple analytical techniques confirmed successful drug entrapment, transformation to amorphous state within lipid matrix, absence of chemical incompatibility, spherical morphology with smooth surface, and sustained release behavior following Higuchi diffusion kinetics. The formulation demonstrated 5-fold enhancement in intestinal permeability compared to pure drug, strongly suggesting improved oral bioavailability potential that directly addresses the fundamental biopharmaceutical limitation of metformin as BCS Class III drug. The sustained release profile with 78.3% drug release over 12hours offers significant clinical advantages including potential for reduced dosing frequency, maintenance of steady plasma levels, minimized gastrointestinal adverse effects, and improved patient compliance. Stability studies confirmed excellent physical and chemical stability under both accelerated and long-term storage conditions, validating commercial viability.

The developed MTF-SLN formulation represents a rational, scientifically sound approach to overcome the poor membrane permeability and low bioavailability limitations of metformin. This nanoformulation holds significant promise for translation into clinical application, potentially reducing required doses, minimizing inter-individual pharmacokinetic variability, and enhancing therapeutic outcomes in type 2 diabetes management. Future studies should focus on pharmacokinetic evaluation in animal models, dose-response studies, long-term efficacy assessment in diabetic models, scale-up optimization for industrial production, and ultimately clinical trials to establish superiority over conventional formulations. The successful development of this nanoformulation exemplifies the transformative potential of nanotechnology in pharmaceutical sciences, offering innovative solutions to longstanding biopharmaceutical challenges and paving the way for next-generation antidiabetic therapies with improved efficacy, safety, and patient acceptance.

5. CONFLICT OF INTEREST:

The authors declare no conflicts of interest in relation to this research work.

6. REFERENCES:

1. American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes. Diabetes Care. 2024; 47(Supplement 1): S20-S42. https://doi.org/10.2337/dc24-S002

2. Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., and Magliano, D. J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice. 2022; 183: 109119. https://doi.org/10.1016/j.diabres.2021.109119

3. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). https://diabetesatlas.org/

4. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., Testa, M. A., and Weiss, R. Type 2 diabetes mellitus. Nature Reviews Disease Primers. 2015; 1: 15019. https://doi.org/10.1038/nrdp.2015.19

5. Forbes, J. M., and Cooper, M. E. Mechanisms of diabetic complications. Physiological Reviews. 2013; 93(1): 137-188. https://doi.org/10.1152/physrev.00045.2011

6. Mohamed, H. A., El-Sayed, N. M., Ismail, M. M., Osman, D. A., and Fahmy, R. H. Metformin-loaded nanoparticles reduce hyperglycemia-induced oxidative stress and vascular dysfunction. Scientific Reports. 2024; 14: 30682. https://doi.org/10.1038/s41598-024-81427-6

7. Chatterjee, S., Khunti, K., and Davies, M. J. Type 2 diabetes. The Lancet. 2017; 389(10085): 2239-2251. https://doi.org/10.1016/S0140-6736(17)30058-2

8. Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Kilov, G., Bavuma, C. M., Jawad, F., Azad Khan, A. K., Katulanda, P., Simons, M., Mgunda, F., and Viswanathan, V. Consensus on medical nutrition therapy for diabesity (obesity and type 2 diabetes mellitus) in the continuum of care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2019; 13(1): 582-590. https://doi.org/10.1016/j.dsx.2018.11.036

9. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024; 47(Supplement 1): S158-S178. https://doi.org/10.2337/dc24-S009

10. Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., and Buse, J. B. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11): 2753-2786. https://doi.org/10.2337/dci22-0034

11. Rena, G., Hardie, D. G., and Pearson, E. R. The mechanisms of action of metformin. Diabetologia. 2017; 60(9): 1577-1585. https://doi.org/10.1007/s00125-017-4342-z

12. Foretz, M., Guigas, B., and Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2023; 19(11): 633-652. https://doi.org/10.1038/s41574-023-00833-4

13. Metry, M., Abdelbary, G., Ahmed, H., Kets, E., and Annaert, P. Biowaiver monographs for immediate release solid oral dosage forms: Metformin hydrochloride. Journal of Pharmaceutical Sciences. 2021; 110(4): 1513-1526. https://doi.org/10.1016/j.xphs.2021.01.011

14. Hou, Z., Li, Y., Huang, Y., Zhou, C., Lin, J., Wang, Y., Cui, F., Zhou, S., Jia, M., Ye, S., and Zhang, Q. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences. 2004; 22(4): 297-304. https://doi.org/10.1016/j.ejps.2004.03.016

15. Chou, F. C., Huang, P. W., and Huang, T. W. (). Determination of the partition coefficient and acid dissociation constant of metformin by capillary electrophoresis. Journal of Food and Drug Analysis. 2002; 10(2): 75-79.

16. Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., Ray, J. E., Timmins, P., and Williams, K. M. Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics. 2011; 50(2): 81-98. https://doi.org/10.2165/11534750-000000000-00000

17. Marathe, P. H., Gao, H. X., and Close, K. L. American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of Diabetes. 2000; 9(4): 320-324. https://doi.org/10.1111/1753-0407.12524

18. Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., and Klein, T. E. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics. 2012; 22(11): 820-827. https://doi.org/10.1097/FPC.0b013e3283559b22

19. Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N., and Pearson, E. R. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009; 58(6): 1434-1439. https://doi.org/10.2337/db08-0896

20. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., and Shin, H. S. Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology. 2018; 16(1): 71. https://doi.org/10.1186/s12951-018-0392-8

21. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., and Langer, R. Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery. 2021; 20(2): 101-124. https://doi.org/10.1038/s41573-020-0090-8

22. Shi, J., Kantoff, P. W., Wooster, R., and Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer. 2017; 17(1): 20-37. https://doi.org/10.1038/nrc.2016.108

23. Müller, R. H., Mäder, K., and Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000; 50(1): 161-177. https://doi.org/10.1016/S0939-6411(00)00087-4

24. Mehnert, W., and Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews. 2012; 64: 83-101. https://doi.org/10.1016/j.addr.2012.09.021

25. Müller, R. H., Radtke, M., and Wissing, S. A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews. 2002; 54(Supplement 1): S131-S155. https://doi.org/10.1016/S0169-409X(02)00118-7

26. Gasco, M. R. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent No. 1993; 5: 250,236.

27. Khosa, A., Reddi, S., and Saha, R. N. Nanostructured lipid carriers for site-specific drug delivery. Biomedical Pharmacotherapy. 2018; 103: 598-613. https://doi.org/10.1016/j.biopha.2018.04.055

28. Das, S., and Chaudhury, A. Preparation of solid lipid nanoparticles and nanostructured lipid carriers using hot melt extrusion technology. Pharmaceutical Development and Technology. 2020; 25(10): 1158-1170. https://doi.org/10.1080/10837450.2020.1809000

29. Qushawy, M., Nasr, A., Abd-Alhaseeb, M., and Swidan, S. Optimized nanostructured lipid carriers for metformin: Enhanced anti-inflammatory activity and protection against type 2 diabetes-induced organ damage. International Journal of Nanomedicine. 2025; 20: 2345-2365. https://doi.org/10.2147/IJN.S445328

30. Cassayre, M., Provost, C., Boudier, A., Clarot, I., and Maincent, P. Optimization of solid lipid nanoparticle formulation using design of experiments and artificial intelligence approaches. Pharmaceutics. 2025; 17(7): 892. https://doi.org/10.3390/pharmaceutics17070892

31. Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., and Mozafari, M. R. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018; 10(2): 57. https://doi.org/10.3390/pharmaceutics10020057

32. Honary, S., and Zahir, F. Effect of zeta potential on the properties of nano-drug delivery systems - A review (Part 2). Tropical Journal of Pharmaceutical Research. 2013; 12(2): 265-273. https://doi.org/10.4314/tjpr.v12i2.20

33. zur Mühlen, A., Schwarz, C., and Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. European Journal of Pharmaceutics and Biopharmaceutics. 1998; 45(2): 149-155. https://doi.org/10.1016/S0939-6411(97)00150-1

34. Freitas, C., and Müller, R. H. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. European Journal of Pharmaceutics and Biopharmaceutics. 1999; 47(2): 125-132. https://doi.org/10.1016/S0939-6411(98)00074-5

35. Thakur, N., Garg, G., and Sharma, P. K. Permeability enhancement of a BCS Class III drug: Metformin using lipid-based nanoparticles. International Journal of Applied Pharmaceutics, 2025; 17(3): 45-53. https://doi.org/10.22159/ijap.2025v17i3.53483

Received on 27.02.2026 Revised on 26.03.2026

Accepted on 20.04.2026 Published on 07.07.2026

Available online from July 10, 2026

Res. J. Pharma. Dosage Forms and Tech.2026; 18(3):193-202.

DOI: 10.52711/0975-4377.2026.00029

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.

Storage Condition	Parameter	Initial	3 Months	6 Months
40°C/75% RH	Particle size (nm)	262.1±5.8	268.3±6.2	275.8±7.1
	PDI	0.352±0.018	0.368±0.021	0.387±0.024
	Zeta potential (mV)	-42.5±1.8	-41.2±2.1	-39.8±2.3
	EE%	95.8±2.3	94.1±2.5	92.3±2.8
	Drug content%	98.6±1.2	97.2±1.5	95.8±1.7
25°C/60% RH	Particle size (nm)	262.1±5.8	264.7±5.9	267.2±6.3
	PDI	0.352±0.018	0.359±0.019	0.365±0.022
	Zeta potential (mV)	-42.5±1.8	-41.8±1.9	-41.1±2.0
	EE%	95.8±2.3	95.2±2.4	94.5±2.6
	Drug content%	98.6±1.2	98.1±1.3	97.5±1.4